

12-16-03

USO 4571.3  
PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Roy Wuthier et al.

Art Unit TBA

Serial No. 10/696,760

Filed October 29, 2003

Confirmation No. TBA

For FC101 AND ANALOGS AS A METHOD OF TREATMENT FOR CANCER

December 15, 2003

TO THE COMMISSIONER FOR PATENTS,

SIR:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, Applicants submit copies of the references on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.


In accordance with M.P.E.P. § 609, Applicants have not submitted copies of reference number 1 as it was previously submitted with related Application No. 10/211,466, filed August 2, 2002, now U.S. Patent No. 6,660,765; and, reference numbers 2 through 25, as they were previously submitted with related Application No. 09/281,577, filed March 30, 1999, now U.S. Patent No. 6,225,340.

Respectfully submitted,

Timothy B. McBride, Reg. No. 47,481  
SENNIGER, POWERS, LEAVITT & ROEDEL  
One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102  
(314) 231-5400

TBM/sxm

Express Mail Label No. EV 327054218 US


PTO/SB/08A  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>   (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/696,760
				Filing Date	10-29-2003
				Confirmation Number	TBA
				First Named Inventor	R. Wuthier et al.
				Group Art Unit	TBA
				Examiner Name	TBA
Sheet	1	of	3	Attorney Docket No.	USO 4571.3

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
		Number	Kind Code <sup>2</sup> (if known)			
	1	5821130	A	Baldwin et al.	10-13-1998	
OTHER ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>6</sup>
	2	ABBAS et al., "Mycotoxins produced by toxic <i>Fusarium</i> isolates obtained from agricultural and nonagricultural areas (Arctic) of Norway," Mycopathologia 1989; 105:143-51.				
	3	ABBAS et al., "Production of trichothecene and non-trichothecene mycotoxins by <i>Fusarium</i> species isolated from maize in Minnesota," Mycopathologia 1989; 108:55-8.				
	4	BROWNLEE, S., "They called his theory ridiculous," U.S. New & World Report 1996, p. 82.				
	5	COOK et al., "Factors influencing growth plate cartilage turnover," Poult Sci 1994; 73:889-96.				
	6	HAYNES et al., "Ultrastructure of <i>Fusarium</i> -induced tibial dyschondroplasia in chickens: a sequential study," Vet Pathol 1986; 23:499-505.				
	7	KIM et al., "Sambutoxin, a new mycotoxin produced by toxic <i>Fusarium</i> isolates obtained from rotted potato tubers." Appl. Environ. Microbiol., 1994, pp. 4380-4386, Vol. 60.				
	8	KROGH et al., "Natural occurrence of the mycotoxin fusarochromanone, a metabolite of <i>Fusarium equiseti</i> , in cereal feed associated with tibial dyschondroplastic," Appl Environ Microbiol 1989; 55:3184-8.				
Examiner Signature		Date Considered				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)  				<b>Complete if Known</b>	
				Application Number	10/696,760
				Filing Date	10-29-2003
				Confirmation Number	TBA
				First Named Inventor	R. Wuthier et al.
				Group Art Unit	TBA
				Examiner Name	TBA
Sheet	2	of	3	Attorney Docket No.	USO 4571.3


	9	LAWLER et al., "Acid phosphatase activity of chondroclasts from Fusarium-induced tibial dyschondroplastic cartilage," Avian Dis 1988; 32:240-5.	
	10	LEE et al., "TDP-1, a Toxic Component Causing Tibial Dyschondroplasia in Broiler Chickens, and Trichothecenes from <i>Fusarium roseum</i> Graminearum," Applied and Environmental Microbiology 1985; p. 102-106.	
	11	MINERVINI et al., "Immunomodulatory effects of fusarochromanones TDP-1 and TDP-2," Nat Toxins 1992; 1:15-18.	
	12	MIROCHA et al., "Absence of trichothecenes in toxigenic isolates of <i>Fusarium moniliforme</i> ," App. Environ Microbiol 1990; 56:520-5.	
	13	MIROCHA et al., "Mycotoxin production by <i>Fusarium oxysporum</i> and <i>Fusarium sporotrichioides</i> isolated from <i>Baccharis</i> spp. from Brazil," Appl Environ Microbiol 1989; 55:254-5.	
	14	NIE, D. et al., "Defect in Formation of Functional Matrix Vesicles by Growth Plate Chondrocytes in Avian Tibial Dyschondroplasia: Evidence of Defective Tissue Vascularization," Journal of Bone and Mineral Research 1995; 10:1625-1634.	
	15	ORTH et al., "Avian tibial dyschondroplasia: a morphological and biochemical review of the growth plate lesion and its causes." Vet Pathol, 1994, pp. 403-414, Vol. 31.	
	16	PATHRE et al., "The structure of fusarochromanone: new mycotoxin from <i>Fusarium roseum</i> , "Graminearum", " Can. J. Chem. 1986; 64:1308-1311.	
	17	POWLOSKY et al., "Mass spectral analysis and fragment ion structure of fusarochromanone," Biol Mass Spectrometry 1991; 20:743-9.	
	18	WALSER et al., "Effect of dietary selenium on the development of Fusarium-induced tibial dyschondroplasia in broiler chickens," Avian Dis 1988; 32:84-8.	
	19	WRIGHT, JR. et al., "Effect of fusarochromanone and T-2 toxin on articular chondrocytes in monolayer culture," Fundam Appl Toxicol 1987; 9:595-7.	
	20	WU et al., "Fusarochromanone production by <i>Fusarium</i> isolates," Appl Environ Microbiol 1990; 56:2989-93.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)  				<b>Complete if Known</b>	
				Application Number	10/696,760
				Filing Date	10-29-2003
				Confirmation Number	TBA
				First Named Inventor	R. Wuthier et al.
				Group Art Unit	TBA
				Examiner Name	TBA
Sheet	3	of	3	Attorney Docket No.	USO 4571.3

	21	WU et al., "Tibial dyschondroplasia of chickens induced by fusarochromanone, a mycotoxin," Avian Dis., 1993, Vol. 37, pp. 302-309.	
	22	XIE et al., "Biosynthesis of furarochromanone and its monoacetyl derivative by <i>Fusarium equiseti</i> ," Appl Environ Microbiol 1989; 55:794-7.	
	23	XIE et al., "Isolation and structure identification of two new derivatives of the mycotoxin fusarochromenone produced by <i>Fusarium equiseti</i> ." J. Nat. Prod., 1995, pp. 124-127, Vol. 58.	
	24	YU et al., "Immunochromatography of fusarochromanone mycotoxins," J Assoc Off Anal Chem 1991; 74:655-60.	
	25	YU et al., "Production and characterization of antibody against fusarochromanone," Food & Agricult Immun 1990; 2:55-64.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.